LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month High After Earnings Beat

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) reached a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $112.65 and last traded at $105.6410, with a volume of 191905 shares trading hands. The stock had previously closed at $91.38.

The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The firm had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same quarter last year, the company posted $0.49 EPS. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be given a $0.25 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, March 12th. This represents a $1.00 annualized dividend and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 31.87%.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Finally, Barrington Research boosted their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of “Hold” and an average target price of $105.80.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently added to or reduced their stakes in the company. M&T Bank Corp grew its position in LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after purchasing an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of LeMaitre Vascular by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after purchasing an additional 231,157 shares during the period. First Trust Advisors LP raised its position in shares of LeMaitre Vascular by 35.4% in the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock valued at $72,541,000 after purchasing an additional 216,919 shares during the period. Millennium Management LLC boosted its holdings in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after buying an additional 105,921 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

The firm has a market cap of $2.45 billion, a price-to-earnings ratio of 43.10, a price-to-earnings-growth ratio of 2.30 and a beta of 0.72. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $87.02 and its 200 day moving average is $88.40.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.